All Title Author
Keywords Abstract

Characteristic Analysis from Excessive to Deficient Syndromes in Hepatocarcinoma Underlying miRNA Array Data

DOI: 10.1155/2013/324636

Full-Text   Cite this paper   Add to My Lib


Traditional Chinese medicine (TCM) treatment is regarded as a safe and effective method for many diseases. In this study, the characteristics among excessive, excessive-deficient, and deficient syndromes of Hepatocellular carcinoma (HCC) were studied using miRNA array data. We first calculated the differentially expressed miRNAs based on random module t-test and classified three TCM syndromes of HCC using SVM method. Then, the weighted miRNA-target networks were constructed for different TCM syndromes using predicted miRNA targets. Subsequently, the prioritized target genes of upexpression network of TCM syndromes were analyzed using DAVID online analysis. The results showed that there are distinctly different hierarchical cluster and network structure of TCM syndromes in HCC, but the excessive-deficient combination syndrome is extrinsically close to deficient syndrome. GO and pathway analysis revealed that the molecular mechanisms of excessive-deficient and deficient syndromes of HCC are more complex than excessive syndrome. Furthermore, although excessive-deficient and deficient syndromes have similar complex mechanisms, excessive-deficient syndrome is more involved than deficient syndrome in development of cancer process. This study suggested that miRNAs might be important mediators involved in the changing process from excessive to deficient syndromes and could be potential molecular markers for the diagnosis of TCM syndromes in HCC. 1. Introduction Hepatocellular carcinoma (HCC) is one of the most common devastating cancer types, ranking sixth in incidence, and the third leading cause of cancer related deaths worldwide [1, 2]. The hepatitis B and hepatitis C infections, idiopathic cirrhosis, and alcoholic liver diseases usually are major risk factors for HCC [3]. For early diagnosis of HCC is difficult, and more than half of the HCC patients are diagnosed too late to benefit from the curative therapies. Furthermore, molecular approaches have revealed many molecular events associated with HCC, yet molecular mechanism of cell proliferation and effective biological markers for driving hepatocarcinogenesis remain largely unknown [4]. Under these circumstances, many failing patients seek to get help from complementary and alternative medicine, especially traditional Chinese medicine (TCM). TCM is an ancient Chinese medicine that evolved through at least three thousand years of uninterrupted clinical practice. The TCM treatment usually uses a traditional diagnosis method to classify the TCM syndromes, which based on clinical symptoms and signs, followed


[1]  M.-F. Yuen, J.-L. Hou, and A. Chutaputti, “Hepatocellular carcinoma in the Asia pacific region,” Journal of Gastroenterology and Hepatology, vol. 24, no. 3, pp. 346–353, 2009.
[2]  G.-S. Feng, “Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox,” Cancer Cell, vol. 21, no. 2, pp. 150–154, 2012.
[3]  H. B. El-Serag, J. A. Davila, N. J. Petersen, and K. A. McGlynn, “The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update,” Annals of Internal Medicine, vol. 139, no. 10, pp. 817–823, 2003.
[4]  H.-C. Hsu, Y.-M. Jeng, T.-L. Mao, J.-S. Chu, P.-L. Lai, and S.-Y. Peng, “β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis,” The American Journal of Pathology, vol. 157, no. 3, pp. 763–770, 2000.
[5]  W. Jia, W.-Y. Gao, Y.-Q. Yan et al., “The rediscovery of ancient Chinese herbal formulas,” Phytotherapy Research, vol. 18, no. 8, pp. 681–686, 2004.
[6]  Y. N. Song, J. J. Sun, Y. Y. Lu, et al., “Therapeutic efficacy of fuzheng-huayu tablet based traditional chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail,” Evidence Based Complementary Alternative Medicine, vol. 2013, Article ID 709305, 8 pages, 2013.
[7]  R. Li, T. Ma, J. Gu, et al., “Imbalanced network biomarkers for traditional Chinese medicine Syndrome in gastritis patients,” Scientific Reports, vol. 3, article 1543, 2013.
[8]  B. Jiang, X. Liang, Y. Chen, et al., “Integrating next-generation sequencing and traditional tongue diagnosis to determine tongue coating microbiome,” Scientific Reports, vol. 2, article 936, 2012.
[9]  A. Esquela-Kerscher and F. J. Slack, “Oncomirs—MicroRNAs with a role in cancer,” Nature Reviews Cancer, vol. 6, no. 4, pp. 259–269, 2006.
[10]  D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009.
[11]  J. Hou, L. Lin, W. Zhou et al., “Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma,” Cancer Cell, vol. 19, no. 2, pp. 232–243, 2011.
[12]  G. Chen, J. Wang, and Q. Cui, “Could circulating miRNAs contribute to cancer therapy?” Trends in Molecular Medicine, vol. 19, no. 2, pp. 71–73, 2013.
[13]  H. Zhang, Q. Y. Li, Z. Z. Guo, et al., “Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B,” World Journal of Gastroenterology, vol. 18, no. 37, pp. 5188–5196, 2012.
[14]  H. Zhang, Y. Guan, Y. Y. Lu, et al., “Circulating miR-583 and miR-663 refer to ZHENG differentiation in chronic hepatitis B,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 751341, 8 pages, 2013.
[15]  Q. L. Chen, Y. Y. Lu, G. B. Zhang, et al., “Progression from excessive to deficient syndromes in chronic hepatitis B: a dynamical network analysis of miRNA array data,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 945245, 10 pages, 2013.
[16]  H. Zhuang, “Guideline on prevention and treatment of chronic hepatitis B in China (2005),” Chinese Medical Journal, vol. 120, no. 24, pp. 2159–2173, 2007.
[17]  “The standards of TCM differential syndromes of viral hepatitis,” Internal Medicine Hepatopathy Committee of Chinese Traditional Medicine Association, December 1991.
[18]  T. Vergoulis, I. S. Vlachos, P. Alexiou, et al., “TarBase 6. 0: capturing the exponential growth of miRNA targets with experimental support,” Nucleic Acids Research, vol. 40, no. D1, pp. D222–D229, 2012.
[19]  X. Wang and I. M. El Naqa, “Prediction of both conserved and nonconserved microRNA targets in animals,” Bioinformatics, vol. 24, no. 3, pp. 325–332, 2008.
[20]  D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.
[21]  D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists,” Nucleic Acids Research, vol. 37, no. 1, pp. 1–13, 2009.
[22]  S. Zheng, W. P. Tansey, S. W. Hiebert, and Z. Zhao, “Integrative network analysis identifies key genes and pathways in the progression of hepatitis C virus induced hepatocellular carcinoma,” BMC Medical Genomics, vol. 4, article 62, 2011.
[23]  A. Krek, D. Grün, M. N. Poy et al., “Combinatorial microRNA target predictions,” Nature Genetics, vol. 37, no. 5, pp. 495–500, 2005.
[24]  Y. Guo, Y. Feng, N. S. Trivedi, and S. Huang, “Medusa structure of the gene regulatory network: dominance of transcription factors in cancer subtype classification,” Experimental Biology and Medicine, vol. 236, no. 5, pp. 628–636, 2011.
[25]  J. A. Miller, S. Horvath, and D. H. Geschwind, “Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 28, pp. 12698–12703, 2010.
[26]  D. He, Z. P. Liu, M. Honda, et al., “Coexpression network analysis in chronic hepatitis B and C hepatic lesions reveals distinct patterns of disease progression to hepatocellular carcinoma,” Journal of Molecular Cell Biology, vol. 4, no. 3, pp. 140–152, 2012.
[27]  A. Spaziani, A. Alisi, D. Sanna, and C. Balsano, “Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1,” Journal of Biological Chemistry, vol. 281, no. 16, pp. 10983–10989, 2006.


comments powered by Disqus

Contact Us


微信:OALib Journal